Maryiam Asghar, M. Rasheed, Amir Akbar, Farhat Jabeen Malik, D. Rai, Liaquat Ali
{"title":"Comparison of Effects Beclomethasone Dipropionate with Flunisolide in Patients with Allergic Rhinitis","authors":"Maryiam Asghar, M. Rasheed, Amir Akbar, Farhat Jabeen Malik, D. Rai, Liaquat Ali","doi":"10.37185/lns.1.1.358","DOIUrl":null,"url":null,"abstract":"Objective: To compare the effectiveness of beclomethasone dipropionate with flunisolide given twice daily in terms of improvement in symptom score after 14 days of treatment in allergic rhinitis patients.Study Design: Quasi-Experimental Study.Place and Duration of Study: The study was carried out at the Department of ENT, PAF Hospital E-9 Islamabad, Pakistan, from January 2021 to July 2021.Materials and Methods: All patients of age 20-60 years of either gender having allergic rhinitis were included in the study. Allergic rhinitis was defined as any patient with a history of running nose with seasonal changes or exposure to allergens diagnosed by a consultant ENT surgeon. Patients with a history of smoking, asthma, having deviated nasal septum and inferior turbinate hypertrophy, patients already treated with Beclomethasone dipropionate or flunisolide, patients having an acute upper respiratory infection, and pregnant females were excluded from the study. A consecutive sampling technique was applied for the selection of participants. Patients were randomly divided into two groups: Group-A was given beclomethasone dipropionate, and Group-B Group-B was given flunisolide. The daily dose during treatment was 0.1 mg of beclomethasone dipropionate (50 ugs per puff) two-time each medicine daily. And dose of flunisolide nasal solution (flunisolide nasal spray 0.025%) flunisolide 50 micrograms in each nostril twice daily were 2 sprays (50 ugs) in each nostril 2 times a day: Treatment was continued for two weeks in each group. The symptoms score was estimated at baseline and after two weeks of intervention. Data were analyzed with the help of SPSS version 20.Results: The mean age of the study participants was 41.17+8.58 years in beclomethasone dipropionate and 41.85+8.52 years in flunisolide. Efficacy of flunisolide was significantly higher in terms of improvement in symptom score after 14 days of treatment in patients of allergic rhinitis compared to beclomethasone dipropionate (85% vs 79.58, p=0.035).Conclusion: Flunisolide inhaler is more effective when compared with beclomethasone dipropionate for treating allergic rhinitis.","PeriodicalId":15254,"journal":{"name":"Journal of Biology and Life Science","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biology and Life Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37185/lns.1.1.358","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To compare the effectiveness of beclomethasone dipropionate with flunisolide given twice daily in terms of improvement in symptom score after 14 days of treatment in allergic rhinitis patients.Study Design: Quasi-Experimental Study.Place and Duration of Study: The study was carried out at the Department of ENT, PAF Hospital E-9 Islamabad, Pakistan, from January 2021 to July 2021.Materials and Methods: All patients of age 20-60 years of either gender having allergic rhinitis were included in the study. Allergic rhinitis was defined as any patient with a history of running nose with seasonal changes or exposure to allergens diagnosed by a consultant ENT surgeon. Patients with a history of smoking, asthma, having deviated nasal septum and inferior turbinate hypertrophy, patients already treated with Beclomethasone dipropionate or flunisolide, patients having an acute upper respiratory infection, and pregnant females were excluded from the study. A consecutive sampling technique was applied for the selection of participants. Patients were randomly divided into two groups: Group-A was given beclomethasone dipropionate, and Group-B Group-B was given flunisolide. The daily dose during treatment was 0.1 mg of beclomethasone dipropionate (50 ugs per puff) two-time each medicine daily. And dose of flunisolide nasal solution (flunisolide nasal spray 0.025%) flunisolide 50 micrograms in each nostril twice daily were 2 sprays (50 ugs) in each nostril 2 times a day: Treatment was continued for two weeks in each group. The symptoms score was estimated at baseline and after two weeks of intervention. Data were analyzed with the help of SPSS version 20.Results: The mean age of the study participants was 41.17+8.58 years in beclomethasone dipropionate and 41.85+8.52 years in flunisolide. Efficacy of flunisolide was significantly higher in terms of improvement in symptom score after 14 days of treatment in patients of allergic rhinitis compared to beclomethasone dipropionate (85% vs 79.58, p=0.035).Conclusion: Flunisolide inhaler is more effective when compared with beclomethasone dipropionate for treating allergic rhinitis.
目的:比较二丙酸倍氯米松与氟尼索内酯治疗14 d后对变应性鼻炎患者症状评分的改善效果。研究设计:准实验研究。研究地点和时间:研究于2021年1月至2021年7月在巴基斯坦伊斯兰堡PAF医院E-9耳鼻喉科进行。材料和方法:所有年龄在20-60岁的过敏性鼻炎患者,不论性别,均纳入研究。过敏性鼻炎被定义为任何有季节性变化或暴露于过敏原的流鼻涕病史的患者,由耳鼻喉外科顾问医生诊断。有吸烟史、哮喘、鼻中隔偏曲、下鼻甲肥大、已接受二丙酸倍氯米松或氟尼索内治疗的患者、有急性上呼吸道感染的患者以及孕妇均排除在研究之外。采用连续抽样的方法选择研究对象。患者随机分为两组:a组给予二丙酸倍氯米松治疗,b组给予氟尼索内治疗。治疗期间每日剂量为二丙酸倍氯米松0.1 mg(每次50 ug),每日2次。氟尼索利特鼻液(氟尼索利特鼻喷剂0.025%)氟尼索利特50微克,每鼻孔喷2次,每鼻孔喷50 ug,每天2次,每组持续治疗2周。在基线和干预两周后对症状评分进行评估。数据采用SPSS version 20进行分析。结果:研究参与者的平均年龄:双丙酸倍氯米松组为41.17+8.58岁,氟尼索内酯组为41.85+8.52岁。在治疗14天后变应性鼻炎患者的症状评分改善方面,氟尼索内的疗效明显高于二丙酸倍氯米松(85% vs 79.58, p=0.035)。结论:氟尼索内吸入剂治疗变应性鼻炎疗效优于二丙酸倍氯米松。